ERNA vs EVMN

Ernexa Therapeutics Inc. vs Evommune, Inc. — Valuation Comparison 2026

ERNA

Biotechnology
Ernexa Therapeutics Inc.
Quality
4.9
out of 10
Value Trap
34
LOW
Price
$11.66
Last close
Models
9/13
Active
VS

EVMN

Biotechnology
Evommune, Inc.
Quality
6.0
out of 10
Value Trap
Price
$23.33
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ERNA Fair ValueERNA Upside EVMN Fair ValueEVMN Upside
Bayesian DCF Intrinsic $3.80 -67.4% $3.93 -83.1%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.01 -92.7% $0.59 -97.6%
Dynamic NAV Asset-Based $11.07 -5.0% $2.55 -89.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ERNA vs EVMN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ERNA vs EVMN — Which Stock Is More Undervalued?

EVMN scores higher with a 6.0/10 quality rating vs ERNA's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Ernexa Therapeutics Inc. (ERNA) and Evommune, Inc. (EVMN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ERNA currently trades at $11.66 with a QOC of 4.9/10, while EVMN trades at $23.33 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).